Alzheimer’s Drugs Market by Drug Type [NMDA Receptor Antagonists and Cholinesterase Inhibitors], Distribution Channel [Hospital Pharmacy, Retail Pharmacy and Online Pharmacy] – Global Outlook & Forecast 2021-2031
According to the deep-dive market assessment study conducted by Growth+ Reports, the global Alzheimer’s drugs market was pegged at ~US$ 4.5 billion in 2020. The market is expected to witness a CAGR of ~7.2% from 2021 to 2031.
Rising prevalence of Alzheimer’s disease, strong product pipeline, growing public and private funding, government initiatives, and increasing awareness programs are some of the pivotal factors propelling the growth of Alzheimer’s drugs market. However, high failure rates of drugs under clinical trials are likely to restrain the market growth.
Government bodies and numerous organizations across the globe are taking initiatives to fast-track the development of Alzheimer’s drug by providing the necessary funding and approvals. For instance, federal funding for USC’s research on Alzheimer’s disease and related dementias grew by more than 400% between 2015 and 2018. USC’s NIH funding for Alzheimer’s was $13.3 million in 2015 and it increased to $68.3 million in 2018.
Alzheimer’s is the fifth-leading cause of death among those aged 65 & older and is also a leading cause of disability & poor health. An estimated 5.8 million Americans aged 65 and older were living with Alzheimer’s dementia in 2020. 80% of this population was aged 75 or older. This number is expected to increase to 13.5 million by 2050. Among people of age 70, 61% of those with Alzheimer’s dementia are expected to die before the age of 80 compared with 30% of people without Alzheimer’s. The rising prevalence of Alzheimer’s disease has increased the demand for the treatment, which in turn is expected to boost the market growth.
The prominent players are continuously focusing on new therapies that will aid to prevent, slow the decline, or improve the symptoms of Alzheimer’s disease. In 2020, there were around 121 drug molecules in 136 trials of AD therapies. Out of 121 drug molecules, around 12 molecules in trials were intended for the target cognitive enhancement and 12 were intended to treat neuropsychiatric & behavioral symptoms. There were 97 molecules that were intend to achieve disease modification, 16 molecules had amyloid and 11 molecules have tau as the primary target or as one of several effects seen in non‐clinical or previous clinical studies. Therefore, strong product pipeline is expected to propel the Alzheimer’s drug market.
Alzheimer’s drug development is considered to have the highest failure rates of all drug research, at 99.6% compared to 81% for cancer, according to Scientific American. The drug development process includes high capital investments, therefore, failures in drug research may prove to be huge loss for companies, thereby discouraging the companies to invest and participate in the clinical trials. In January 2018, Pfizer, announced to end its R&D on new drugs for Alzheimer’s and Parkinson’s diseases and reallocate the funding to areas where the company has strong scientific leadership. Pfizer is among the first companies to research Alzheimer’s. Such instances are expected to slow down the growth of the market.
The Asia Pacific region is projected to be the fastest growing Alzheimer’s drugs market. The high growth of region can mainly be attributed to developing healthcare infrastructure, increasing investments by public and private sectors, and increasing number of clinical trials in the region owing to less stringent regulation. Countries such as India, China, and Japan in the APAC region, are projected to offer significant growth opportunities owing to the rising geriatric population.
Some of the prominent players operating in the Alzheimer’s drugs market are Daiichi Sankyo Company, Ltd, H. Lundbeck A/S, Novartis AG, Lupin Pharmaceuticals, Inc., Actiza Pharmaceutical Private Limited, Amneal Pharmaceuticals LLC., AC Immune, F. Hoffmann-La Roche Ltd, Janssen Global Services, and LLC, AbbVie Inc., among others.